FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound FSD-201, by down-regulating the cytokines to effectuate an anti-inflammatory response.

Feb 10, 2023 · The Letter of No Objection covers the company’s proposed Phase 1 clinical trial of LUCID-21-302 or Lucid-MS, a novel drug candidate for the treatment of Multiple Sclerosis and provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.

FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to complement existing efforts August 26, 2021 FSD Pharma signs definitive agreement to acquire 100% of Lucid Psycheceuticals Inc.

• FSD-201 is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA) • FSD Pharma’s successfully completed Phase 1 clinical trial showed FSD-201 to be safe and well tolerated

Jul 13, 2020 · FSD Pharma Announces US$20M At-The-Market Offering TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has entered into an Equity Distribution Agreement dated July 10, 2020 (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”).

FSD Pharma ‘thrilled’ to begin Phase 1 studies of its micro-PEA drug in Australia. March 11, 2021. Receive most valuable updates straight into your inbox. SIGN UP TODAY. PLEASE SEND INVESTOR INQUIRIES TO [email protected] ALL OTHER …

Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour's drive from Toronto, FV Pharma management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world.

Jun 4, 2019 · FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome.

FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases.

Sep 13, 2018 · As part of the LOI, FSD Jamaica will establish an experimental centre for the development of cannabis and cannabinoid ("CBD") genetics suitable to cultivate in Jamaica with the intent to create a genetics and seed bank of innovative cannabis and hemp products for the